TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 50126

Group type: EXPERIMENTAL
Intervention: Bleomycin intramuscularly
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bleomycin via continuous infusion
Number of subjects: 15
Study: 29156985

Group type: EXPERIMENTAL
Intervention: Isolated Lumbar Extension (ILEX) exercise for the lumbar extensors, 12-week intervention
Number of subjects: 9
Study: 31628043

Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg twice daily plus best supportive care
Number of subjects: 768

Group type: COMPARATOR
Intervention: Matched placebo plus best supportive care
Number of subjects: 768
Study: 29131730

Group type: EXPERIMENTAL
Intervention: Yoga intervention (10-week trauma-focused yoga program)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 50
Study: 25038079

Group type: EXPERIMENTAL
Intervention: 12-week cycle ergometer-based training at moderate exertion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control period (similar to training period)
Number of subjects: 24
Study: 23525448

Group type: EXPERIMENTAL
Intervention: PSI-697 600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P-selectin-blocking antibody (CLB-Thromb6)
Number of subjects: 0
Study: 22040180

Group type: EXPERIMENTAL
Intervention: Harmonic Focus
Number of subjects: 105

Group type: COMPARATOR
Intervention: Classic suture ligation
Number of subjects: 105
Study: 19236499

Group type: EXPERIMENTAL
Intervention: Multiparametric CT-based i.v. thrombolysis after 3-9 h of symptom onset
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard CT-based thrombolysis within 3 h
Number of subjects: 200

Group type: COMPARATOR
Intervention: CT-based thrombolysis or placebo after 3-6 h
Number of subjects: 200
Study: 16846587

Group type: EXPERIMENTAL
Intervention: Weekly betamethasone
Number of subjects: 495

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 495
Study: 12618675

Group type: EXPERIMENTAL
Intervention: Akinosi technique
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional mandibular nerve block
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 56
Study: 10681341

Group type: EXPERIMENTAL
Intervention: Regimen A (1,920 mg over 3 days, four doses)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Regimen B (2,780 mg over 3 days, six doses)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Regimen C (2,780 mg over 5 days, six doses)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Normal meal close to drug administration
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Higher-dose regimens (B and C)
Number of subjects: 266
Study: 9085958

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% at 6, 8, 10, 12, or 14 mL/h for 21 hours
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 125

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 125
Study: 7881655

Group type: EXPERIMENTAL
Intervention: Selection methods for FEV1
Number of subjects: 5885

Group type: EXPERIMENTAL
Intervention: Selection methods for FVC
Number of subjects: 5885

Group type: EXPERIMENTAL
Intervention: Mean of the three highest values and the largest single value from all maneuvers
Number of subjects: 5885
Study: 2689262

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 31612079

Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise (AAE) on a treadmill at 60% of VO2max for 30 min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Korean black raspberry (KBR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28774461

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15mg/kg every 3 weeks) with carboplatin (AUC 5) and weekly paclitaxel (80mg/m2) for at least 6 cycles
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy
Number of subjects: 33
Study: 25376448

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg BIW for 12 weeks followed by 50 mg QW for 12 weeks
Number of subjects: 270

Group type: COMPARATOR
Intervention: Etanercept (ETN) 50 mg QW for 12 weeks followed by 50 mg QW for 12 weeks
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg BIW/QW
Number of subjects: 270

Group type: COMPARATOR
Intervention: Etanercept (ETN) 50 mg QW/QW
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Patients with severe itching at baseline (score of 5)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Overall patients with clinically meaningful pruritus improvement
Number of subjects: 270
Study: 22743849

Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment (RFT) of the soft palate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined radiofrequency-assisted uvulopalatoplasty (RF-UPP)
Number of subjects: 32
Study: 21211796

Group type: EXPERIMENTAL
Intervention: Medical clowning after embryo transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no medical clowning)
Number of subjects: 0
Study: 19061699

Group type: EXPERIMENTAL
Intervention: Transradial approach
Number of subjects: 3198

Group type: EXPERIMENTAL
Intervention: Transradial access
Number of subjects: 3198

Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 3198

Group type: COMPARATOR
Intervention: Recent myocardial infarction
Number of subjects: 3198

Group type: COMPARATOR
Intervention: Age (per 10 years increase)
Number of subjects: 3198

Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 3198
Study: 16873594

Group type: EXPERIMENTAL
Intervention: Face-to-face motivational interviewing plus telephone counseling and offering of medication
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 114
Study: 12635910

Group type: EXPERIMENTAL
Intervention: Stereotype-consistent behavioral information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotype-inconsistent behavioral information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotype-neutral information
Number of subjects: 0
Study: 11218882

Group type: EXPERIMENTAL
Intervention: Mannitol used within 24 h after the onset (n = 46)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No mannitol used (n = 47)
Number of subjects: 93
Study: 9338905

Group type: EXPERIMENTAL
Intervention: GEN‐EPI
Number of subjects: 30

Group type: COMPARATOR
Intervention: GEN
Number of subjects: 30
Study: 8237823

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 0
Study: 3847416

Group type: EXPERIMENTAL
Intervention: Method A
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Method B
Number of subjects: 50
Study: 31344434

Group type: COMPARATOR
Intervention: Single fraction palliative radiation therapy (8 Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fractionated palliative radiation therapy (24 Gy in 6 fractions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients whose pain improved after palliative radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single fraction palliative radiation therapy (8 Gy) including reirradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fractionated palliative radiation therapy (24 Gy in 6 fractions) including reirradiation
Number of subjects: 0
Study: 30104895

Group type: COMPARATOR
Intervention: Laser Disc Decompression Group (LDG) - 1500 J of laser irradiation into the disc center
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ozone Injection Group (OZG) - 6 mL of ozone 30 µg/mL injected into the center of the disc
Number of subjects: 40
Study: 27434505

Group type: EXPERIMENTAL
Intervention: Buprenorphine buccal film (BBUP)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Placebo buccal film
Number of subjects: 511
Study: 25420433

Group type: EXPERIMENTAL
Intervention: Abstracts with a limitations section
Number of subjects: 300

Group type: COMPARATOR
Intervention: Abstracts without a limitations section
Number of subjects: 300
Study: 19793332

Group type: EXPERIMENTAL
Intervention: Vinylsiloxanether (ID)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vinylsiloxanether with additional splinting (IDF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Polyether (IM)
Number of subjects: 10
Study: 21034888

Group type: EXPERIMENTAL
Intervention: Peptide-based formula with 3.5 g fructo-oligosaccharides and 3.8 g insoluble fiber/L
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control formula (fiber-free)
Number of subjects: 14
Study: 18579709

Group type: EXPERIMENTAL
Intervention: Interactive workshops on chlamydia
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control workshops on management of urinary symptoms
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Modified laboratory request forms
Number of subjects: 82
Study: 16045137

Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Number of subjects: 91

Group type: COMPARATOR
Intervention: Levobupivacaine 0.75%
Number of subjects: 91
Study: 14508939

Group type: EXPERIMENTAL
Intervention: Protective bandage
Number of subjects: 130

Group type: COMPARATOR
Intervention: Allevyn Heel hydrocellular dressing
Number of subjects: 130
Study: 10367542

Group type: EXPERIMENTAL
Intervention: Saccharose (10% solution, 100 ml)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Glucose (10% solution, 100 ml)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mannitol (10% solution, 100 ml)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Isomalt (10% solution, 100 ml)
Number of subjects: 22
Study: 7669959

Group type: EXPERIMENTAL
Intervention: R 80122 (n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Solvent (n = 6)
Number of subjects: 12
Study: 2343719

Group type: EXPERIMENTAL
Intervention: Ventilation by experienced senior anaesthetist
Number of subjects: 198

Group type: COMPARATOR
Intervention: Ventilation by inexperienced junior anaesthetist
Number of subjects: 198
Study: 7039645

Group type: EXPERIMENTAL
Intervention: General anaesthesia plus extradural analgesia (T8‐S5)
Number of subjects: 13

Group type: COMPARATOR
Intervention: General anaesthesia (halothane and nitrous oxide)
Number of subjects: 13
Study: 31909887

Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day isoniazid (INH)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 mg/kg/day isoniazid (INH)
Number of subjects: 24
Study: 30900406

Group type: EXPERIMENTAL
Intervention: Liquid meal condition
Number of subjects: 42

Group type: COMPARATOR
Intervention: Water condition
Number of subjects: 42
Study: 28461159

Group type: EXPERIMENTAL
Intervention: Vitamin D (200,000 IU initial dose followed by 100,000 IU monthly)
Number of subjects: 5110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5110
Study: 26823746

Group type: EXPERIMENTAL
Intervention: Low volume of 7 ml/kg IBW with 8 cm H2O PEEP and recruitment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Low volume of 7 ml/kg IBW with 8 cm H2O PEEP
Number of subjects: 63

Group type: COMPARATOR
Intervention: High volume of 9 ml/kg IBW with ZEEP
Number of subjects: 63
Study: 24816611

Group type: EXPERIMENTAL
Intervention: Health coaching intervention (11 sessions over 6 months)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Usual-care (control) group
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Health coaching intervention (in survivors aged > 60 years)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Health coaching intervention (in male survivors)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Health coaching intervention (in nonobese survivors)
Number of subjects: 410
Study: 23017825

Group type: EXPERIMENTAL
Intervention: Working memory
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Negative symptoms
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Social cognition
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Verbal learning
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Visual learning
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: General symptoms
Number of subjects: 117
Study: 19338691

Group type: EXPERIMENTAL
Intervention: Family Check-Up intervention
Number of subjects: 731
Study: 17295604

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg/d)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg/twice weekly)
Number of subjects: 42
Study: 15114301

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (Certoparin 3000 IU subcutaneously)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo (saline solution 0.3 mL subcutaneously)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study: 11504286

Group type: EXPERIMENTAL
Intervention: Helium insufflation
Number of subjects: 18

Group type: COMPARATOR
Intervention: CO2 insufflation
Number of subjects: 18
Study: 9467533

Group type: COMPARATOR
Intervention: TRH
Number of subjects: 20

Group type: COMPARATOR
Intervention: TRH + GHRP-2
Number of subjects: 20

Group type: COMPARATOR
Intervention: TRH + GHRH + GHRP-2
Number of subjects: 20

Group type: COMPARATOR
Intervention: GHRP-2
Number of subjects: 20

Group type: COMPARATOR
Intervention: GHRH + GHRP-2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TRH + GH secretagogues
Number of subjects: 20

Group type: COMPARATOR
Intervention: TRH alone
Number of subjects: 20
Study: 7841946

Group type: EXPERIMENTAL
Intervention: Storage at -80 degrees C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Storage at -20 degrees C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Storage at room temperature for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Storage at 4 degrees C for 5 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Storage at -40 degrees C
Number of subjects: 0
Study: 3045278

Group type: EXPERIMENTAL
Intervention: Carnoy's fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formalin fixation
Number of subjects: 0
Study: 31751163

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg plus carboplatin plus paclitaxel or nab-paclitaxel
Number of subjects: 1107

Group type: COMPARATOR
Intervention: Placebo plus carboplatin plus paclitaxel or nab-paclitaxel
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Both groups (pembrolizumab and placebo)
Number of subjects: 1107
Study: 29506561

Group type: EXPERIMENTAL
Intervention: Placebo adherence (at least 80%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo non-adherence (never adhered)
Number of subjects: 0
Study: 27316483

Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg twice daily for 6 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: atenolol 50 mg daily for 6 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: ivabradine vs atenolol
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 82

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 82
Study: 25795621

Group type: EXPERIMENTAL
Intervention: Active stimulation (oscillating square wave tDCS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study: 23106175

Group type: EXPERIMENTAL
Intervention: Support group intervention (residential for one week, followed by four days of follow-up two months later)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Support group intervention
Number of subjects: 382

Group type: COMPARATOR
Intervention: Routine control group
Number of subjects: 382
Study: 20646562

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) without low molecular heparin (LMWH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) combined with low molecular heparin (LMWH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-controlled intravenous analgesia (PCIA) without low molecular heparin (LMWH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-controlled intravenous analgesia (PCIA) combined with low molecular heparin (LMWH)
Number of subjects: 0
Study: 18653492

Group type: EXPERIMENTAL
Intervention: Sugammadex (2.0 mg kg(‐1)) administered at reappearance of the second twitch of the TOF.
Number of subjects: 30
Study: 16580371

Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (no assisted hatching)
Number of subjects: 172
Study: 12770960

Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study: 10997756

Group type: EXPERIMENTAL
Intervention: Ventricular resynchronization therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ventricular resynchronization therapy combined with cardioverter-defibrillator capability
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal pharmacological therapy alone
Number of subjects: 0
Study: 9057141

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing with reaming
Number of subjects: 81

Group type: COMPARATOR
Intervention: Intramedullary nailing without reaming
Number of subjects: 81
Study: 8116822

Group type: EXPERIMENTAL
Intervention: Twelve-Step Facilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Coping Skills
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 0
Study: 3734141

Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alcohol 0.8 g/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diazepam and Alcohol interaction
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Buspirone and Alcohol interaction
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Buspirone and Diazepam pharmacokinetics
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single dose of buspirone
Number of subjects: 24
Study: 29473354

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Dachangshu (BL 25) and Shangjuxu (ST 37) combined with ulinastatin, treatment duration: 2 weeks, frequency: once daily for 20 minutes.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine western medicine with intravenous drip of ulinastatin (Control group).
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Dachangshu (BL 25) and Shangjuxu (ST 37) combined with ulinastatin.
Number of subjects: 120
Study: 26816234

Group type: EXPERIMENTAL
Intervention: 200 mg/day of Physta® standardized root water extract of Eurycoma longifolia (Tongkat Ali) for 4 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Rice powder as placebo for 4 weeks
Number of subjects: 84
Study: 24751172

Group type: COMPARATOR
Intervention: CMX-2043
Number of subjects: 0
Study: 23605952

Group type: EXPERIMENTAL
Intervention: Barasertib 1200 mg (7-day intravenous infusion)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Low-dose cytosine arabinoside (LDAC) 20 mg (subcutaneously twice daily for 10 days)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Barasertib
Number of subjects: 74

Group type: COMPARATOR
Intervention: LDAC
Number of subjects: 74
Study: 19952712

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continued protease inhibitor regimen
Number of subjects: 50
Study: 18720881

Group type: EXPERIMENTAL
Intervention: Desloratadine and normal sodium spray
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Desloratadine and Nasonex spray
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo and normal sodium spray
Number of subjects: 50
Study: 15820828

Group type: EXPERIMENTAL
Intervention: Vaginal bromocriptine suppositories with Pluronic F127
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaginal application of bromocriptine tablets
Number of subjects: 0
Study: 12680813

Group type: EXPERIMENTAL
Intervention: Information plus role-play experience
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information alone
Number of subjects: 0
Study: 10230004

Group type: EXPERIMENTAL
Intervention: Immobilization with plaster cast
Number of subjects: 33

Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (dominant and non-dominant injured side)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Non-dominant injured side
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pain during measurements
Number of subjects: 33
Study: 8917026

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ranitidine at 6.25 mg/hr (n = 9)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 20
Study: 1679446

Group type: EXPERIMENTAL
Intervention: 70% isopropanol (IPA) applied for 2 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 70% isopropanol (IPA) applied for 30 s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hibiscrub (chlorhexidine scrub)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorhexidine scrubs (four types)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7.5% povidone-iodine scrub
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% triclosan cleanser
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmedicated bar soap
Number of subjects: 0
Study: 6223819

Group type: EXPERIMENTAL
Intervention: Adjunctive medroxyprogesterone acetate (MPA)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 29286983

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AEx)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretching and Toning (ST)
Number of subjects: 0
Study: 28597981

Group type: EXPERIMENTAL
Intervention: Project Child (patient perspective)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Project Treatment (interviewer perspective)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus group interviews
Number of subjects: 0
Study: 27402021

Group type: EXPERIMENTAL
Intervention: Hypoxia (FiO2 12.5%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normoxia (FiO2 20.0%)
Number of subjects: 30